Drugs / VA111913
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00963053 | Aug 2009 → Sep 2010 | primary dysmenorrhea | Vantia Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VA111913 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00963053 ↗ |
| Action | Inhibit | “VA111913 inhibits vasopressin-induced contractions of human myometrial strips and human myometrial blood vessels in vitro.” NCT00963053 ↗ |
| Route | Oral | “Repeated, Oral Doses of VA111913 TS” NCT00963053 ↗ |